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Summary. Background: According to FDA guidelines, liraglutide should be used on the basis of careful consideration 
in pregnant women with Type 2 diabetes mellitus. The aim of the present study was to record the concentration of lira-
glutide in maternal and umbilical vein serum from a pregnant woman treated with liraglutide. Case report: The pregnant 
woman we present in this case report is a 28-year-old diagnosed with Type 2 diabetes mellitus for 7 years. In spite of 
high insulin dose her glycaemia was poorly controlled, she developed dyslipidaemia and her body weight increased; 
thus, her diabetologist prescribed liraglutide injections and metformin. At booking, obstetrical ultrasound confirmed 
intrauterine pregnancy of 8 gestational weeks. The patient was informed about all possible consequences for her foetus 
that might be caused by liraglutide therapy during pregnancy. She continued her treatment with liraglutide and metfor-
min medication throughout pregnancy. Her pregnancy was terminated by elective Caesarean section at 39 gestational 
weeks; a healthy newborn male was delivered. The concentration of liraglutide was measured in maternal and umbilical 
vein serum. Conclusion: There was no significant transfer of liraglutide from the circulation of the treated mother to her 
fetus, at least 3.5 h after the drug application.
introduction
According to FDA guidelines, liraglutide should be 
used on the basis of careful consideration, and the phy-
sician needs to decide whether the benefit-risk profile is 
favorable for the specific patient (1).
Liraglutide is an injectable glucose-lowering drug, a 
glucagon-like peptide-1 (GLP-1) that is used as a long-
acting GLP-1 receptor agonist, binding to the same re-
ceptors as the endogenous metabolic hormone GLP-1 
that stimulates insulin secretion (2,3).
Liraglutide causes a reduction in body weight and fat 
mass by suppressing energy intake and promoting satiety 
(4,5). Animal reproductive data have revealed evidence 
of the negative impact of therapy with liraglutide (1).
case report
The pregnant woman we present in this case report is 
a 28-year-old diagnosed with Type 2 diabetes for 7 
years. Other significant medical history includes a thy-
roidectomy (histopathology analysis: Struma diffusa 
glandulae thyroideae) and cholecystectomy because of 
gall stones.
During her first pregnancy, her Type 2 diabetes mel-
litus was treated with insulin analogues (insulin aspart 
and insulin detemir). She delivered at term, by a Caesar-
ean section (CS), a healthy newborn male (birthweight 
3650 grams/49 centimeters long). After delivery, insulin 
analogues were continued for diabetes treatment. How-
ever, her glycaemia was poorly controlled, with average 
glycaemia at 9.2 mmol/l, HbA1c beyond 7.5% (58 
mmol/mol); and she developed dyslipidemia as well. 
Moreover, her body weight increased; thus, her diabe-
tologist prescribed liraglutide injections at a dose of 1.8 
mg once a day, and metformin (3x500 mg daily) from 
2014 until today. As a result of the new therapy, her 
glycaemia was normalized, her body weight stabilized, 
and her lipid profile values remained moderately above 
reference values.
This is her second spontaneous pregnancy. Her body 
height measured before pregnancy was 183 cm, and her 
body weight was 139 kg. At booking, obstetrical ultra-
sound revealed intrauterine pregnancy of 8 gestational 
weeks (GW). A balanced diabetic diet of 1300 Kcal/day 
was recommended. Her diabetic pharmacotherapy at 
the time of admission was liraglutide 1.8 mg once daily, 
metformin 500 mg three times daily and levothyroxin 
250 µg once daily throughout the entire pregnancy and 
after delivery.
Daily mean capillary blood glucose values ranged 
from 3.5 – 5.6 mmol/l. HbA1c was 6.5% (48 mmol/mol) 
in the first trimester, and 6.1% (43 mmol/mol) in the 
second and third trimester. The patient was informed by 
a diabetologist and signed a patient’s consent indicating 
that she is completely aware of all possible consequenc-
es to her foetus that might be caused by liraglutide ther-
apy during pregnancy.
The elective CS was performed with spinal anesthe-
sia at 39 GW. At 7 AM on 21 November 2016, she re-
ceived liraglutide 1.8 mg, metformin 500 mg, and a 5% 
glucose 500 ml IV infusion was started. Maternal blood 
sample was taken at the time of CS. At 10:34 AM, a 
healthy newborn male weighing 4220 g and 51 cm long 
was delivered, AS 10/10, and umbilical vein blood was 
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withdrawn. The concentration of liraglutide was mea-
sured with an active GLP-1 ELISA (High Sensitivity 
GLP-1 Active Chemiluminescent ELISA kit, Millipore 
Corporation, St. Charles, Missouri, USA). The levels of 
umbilical vein blood liraglutide, measured with GLP-1 
assay after removal of endogenous GLP-1 by thermal 
degradation (37°C, 4h) were below the limit of assay 
sensitivity declared by manufacturer (2 pmol/L). Simi-
lar result was found in serum of the control pregnant 
woman, wich was <2 pmol/L and far below reported 
reference range for GLP-1 in healthy population (12.7 
pmol/L (8.0–17.1) (6). Our results indicate that: a) re-
moval of endgenous GLP-1 was succesful and reported 
results in serum of treated woman indicate indeed lira-
glutide concentration, and, b) there was no significant 
transfer of liraglutide from the circulation of the treated 
mother to her fetus, at least 3.5 h after the drug applica-
tion as documented in this case. The values of total bili-
rubin, total calcium, AST, ALT, AF, GGT and LDH in 
the serum of the umbilical vein did not differ between 
the pregnant woman taking liraglutide and the healthy 
pregnant control w/o liraglutide. The child is now 2 
years old, healthy and progressing well.
discussion
In this article, we document the concentration of lira-
glutide in maternal and umbilical vein serum from a 
pregnant woman with Type 2 diabetes, treated with lira-
glutide injections.
According to the accessible literature, this is the first 
case to our knowledge of a pregnant woman with Type 
2 diabetes mellitus who was treated with liraglutide and 
metformin during pregnancy and childbirth, and who 
gave birth to a healthy baby. This is the first time the 
concentrations of liraglutide in the mother’s and um-
bilical vein blood were measured, due to the Type 2 dia-
betes mellitus treated with liraglutide from preconcep-
tion throughout pregnancy.
A few years ago, a pregnant woman with diabetes (7) 
was treated with liraglutide during the first 13 weeks of 
pregnancy; liraglutide was replaced with insulin, and 
she gave birth to a healthy baby.
conclusion
There was no significant transfer of liraglutide from 
the circulation of the treated mother to her fetus, at least 
3.5 h after the drug application as documented in this 
case.
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Table 1. Concentration* of active GLP-1 in maternal and umbilical vein 
serum from pregnancy complicated with type 2 diabetes mellitus exposed 
to liraglutide compared to the maternal and umbilical vein serum from 
the healthy pregnant control and was not exposed to liraglutide
Sample pmol/l
Patient exposed to liraglutide Maternal serum 8.4
Umbilical vein serum 0.7
Control patient Maternal serum 1.4
Umbilical vein serum 0.6
The concentration* of liraglutide was measured with an active GLP-1 
ELISA (High Sensitivity GLP-1 Active Chemiluminescent ELISA kit, 
Millipore Corporation, St. Charles, Missouri, USA).
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Sažetak. Prema FDA kategorizaciji lijekova liraglutide treba koristiti tijekom trudnoće samo ako potencijalna korist 
opravdava potencijalni rizik za fetus. Cilj je prikazati trudnicu koja je liječena liraglutidom tijekom cijele trudnoće i 
rodila zdravo dijete. Prikaz trudnice. Uspoređena je koncentracija aktivnog GLP-1 (active GLP-1) u serumu majke i 
umbilikalne vene trudnice koja je liječena liraglutidom i trudnice koja nije bila na terapiji s liraglutidom. Koncentracija 
aktivnog GLP-1 u serumu majke neposredno prije porođaja, odnosno nakon 3 sata i 34 minute od davanja 1,8 mg lira-
glutida, iznosila je 8,4 pmol/l, u umbilikalnom venskom serumu 0,7 pmol/L. U usporedbi sa serumom majke koja nije 
uzimala liraglutide koncentracija aktivnog GLP-1 iznosila je 1,4 pmol/l, a umbilikanom venskom serumu 0,6 pmol/l. 
Zaključak. Koncentracija aktivnog GLP-1 seruma umbilikalne vene majke koja je bila na terapiji s liraglutidom se nije 
razlikovala od koncentracije seruma umbiliklane vene majke koja nije uzimala liraglutid.
